Pharmaceutical intermediates
Iguratimod Intermediates
3 pharmaceutical intermediates for Iguratimod. Indication: Rheumatoid arthritis.
About Iguratimod
- Originator
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Indication
- Rheumatoid arthritis
- Approved Date
- 04/21/2008
Available intermediates
3 intermediates currently listed for Iguratimod. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| N-(4-glycyl-5-methoxy-2-phenoxyphenyl)methanesulfonamide hydrochloride | 149436-41-9 | / | / |
| N-(5-Methoxy-2-phenoxyphenyl)methanesulfonamide | 123664-84-6 | / | / |
| N-[4-[(Formylamino)acetyl] -5-hydroxy-2- phenoxyphenyl]methanesulfonamide | 149457-03-4 | / | / |
Building toward Iguratimod?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →